CDC panel backs Merck's Enflonsia for RSV prevention in infants; FDA-approved therapy reduced hospitalizations by 84% in ...

An outside group of experts agreed that the CDC should recommend a new antibody drug that offers protection against RSV for ...

A newly configured federal vaccine panel's June 25 action is expected to improve options to protect infants from potentially ...

US pharma major Merck & Co has secured a key endorsement for its newly approved respiratory syncytial virus (RSV) prevention ...

U.S. Health Secretary Robert F. Kennedy Jr.'s newly revamped vaccine advisory panel voted on Thursday to recommend Americans ...

Enjoy, and see you soon… A fast-growing group of Americans is turning to what many call the “gray market” for obesity ...

Enflonsia is an extended half-life RSV fusion glycoprotein neutralizing monoclonal antibody that is designed to provide durable protection through 5 months.